148 related articles for article (PubMed ID: 19412908)
1. A combined molecular modeling study on gelatinases and their potent inhibitors.
Xi L; Du J; Li S; Li J; Liu H; Yao X
J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908
[TBL] [Abstract][Full Text] [Related]
2. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
3. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
[TBL] [Abstract][Full Text] [Related]
4. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase.
Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P
Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
[TBL] [Abstract][Full Text] [Related]
6. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
7. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
8. QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.
Fernández M; Caballero J
Bioorg Med Chem; 2007 Sep; 15(18):6298-310. PubMed ID: 17590339
[TBL] [Abstract][Full Text] [Related]
9. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
11. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
Matter H; Schwab W; Barbier D; Billen G; Haase B; Neises B; Schudok M; Thorwart W; Schreuder H; Brachvogel V; Lönze P; Weithmann KU
J Med Chem; 1999 Jun; 42(11):1908-20. PubMed ID: 10354399
[TBL] [Abstract][Full Text] [Related]
13. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
15. Highly predictive CoMFA and CoMSIA models for two series of stromelysin-1 (MMP-3) inhibitors elucidate S1' and S1-S2' binding modes.
Amin EA; Welsh WJ
J Chem Inf Model; 2006; 46(4):1775-83. PubMed ID: 16859309
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II.
Huang H; Pan X; Tan N; Zeng G; Ji C
Eur J Med Chem; 2007 Mar; 42(3):365-72. PubMed ID: 17118494
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
18. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques.
Tsai KC; Lin TH
J Chem Inf Comput Sci; 2004; 44(5):1857-71. PubMed ID: 15446846
[TBL] [Abstract][Full Text] [Related]
19. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]